Acuta Capital Partners, LLC Protagonist Therapeutics, Inc Transaction History

Acuta Capital Partners, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 14, 2020	SELL	$4.69 - $13.45 $1.96 Million - $5.63 Million	-418,500 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$9.41 - $16.56 $2.38 Million - $4.19 Million	-253,000 Reduced 37.68%	418,500 $5.03 Million
Q2 2019 Aug 14, 2019	BUY	$8.98 - $12.96 $3 Million - $4.33 Million	334,000 Added 98.96%	671,500 $8.13 Million
Q1 2019 May 14, 2019	BUY	$6.5 - $13.77 $2.19 Million - $4.65 Million	337,500 New	337,500 $4.24 Million

195

58.7M

20.8K

109K

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $2.19B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

Get notified when there are updates to the investment portfolio of Acuta Capital Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Acuta Capital Partners, LLC with notifications on news.